title: Genetically-engineered mouse models for pancreatic cancer: Advances and current limitations.
abstract: Recently, there has been significant progress in the development of genetically-engineered mouse (GEM) models. By introducing genetic alterations and/or signaling alterations of human pancreatic cancer into the mouse pancreas, animal models can recapitulate human disease. Pancreas epithelium-specific endogenous Kras activation develops murine pancreatic intraepithelial neoplasia (mPanIN). Additional inactivation of p16, p53, or transforming growth factor-β signaling, in the context of Kras activation, dramatically accelerates mPanIN progression to invasive pancreatic ductal adenocarcinoma (PDAC) with abundant stromal expansion and marked fibrosis (desmoplasia). The autochthonous cancer models retain tumor progression processes from pre-cancer to cancer as well as the intact tumor microenvironment, which is superior to xenograft models, although there are some limitations and differences from human PDAC. By fully studying GEM models, we can understand the mechanisms of PDAC formation and progression more precisely, which will lead us to a breakthrough in novel diagnostic and therapeutic methods as well as identification of the origin of PDAC.
authors: Hideaki Ijichi, Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
authors: Hideaki
authors: H
authors: Ijichi
references: Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4437-42
references: 17360542
references: Nat Biotechnol. 2010 Jun;28(6):585-93
references: 20495549
references: Nat Rev Cancer. 2002 Dec;2(12):897-909
references: 12459728
references: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references: 19474385
references: Cancer Cell. 2005 May;7(5):469-83
references: 15894267
references: Cancer Cell. 2009 Nov 6;16(5):379-89
references: 19878870
references: Cancer Cell. 2007 Mar;11(3):291-302
references: 17349585
references: Cancer Cell. 2007 Mar;11(3):229-43
references: 17349581
references: Genes Dev. 2006 Nov 15;20(22):3147-60
references: 17114585
references: Genes Dev. 2006 Nov 15;20(22):3130-46
references: 17114584
references: Cancer Res. 1998 Dec 1;58(23):5329-32
references: 9850059
references: Cancer Res. 2006 Jan 1;66(1):95-106
references: 16397221
references: Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18913-8
references: 19028870
references: Cancer Cell. 2003 Dec;4(6):437-50
references: 14706336
references: Gut. 2008 Oct;57(10):1420-30
references: 18515410
references: J Epidemiol. 2005 Jun;15 Suppl 2:S150-6
references: 16127227
references: Science. 2009 Jun 12;324(5933):1457-61
references: 19460966
references: Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18907-12
references: 19028876
references: Anticancer Res. 2000 Jan-Feb;20(1A):43-51
references: 10769633
references: Science. 1996 Jan 19;271(5247):350-3
references: 8553070
references: PLoS Med. 2008 Jun 10;5(6):e123
references: 18547137
references: Cancer Res. 2007 Sep 1;67(17):8121-30
references: 17804724
references: Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5947-52
references: 16585505
references: Pancreas. 2004 Apr;28(3):219-30
references: 15084961
references: Genes Dev. 2003 Dec 15;17(24):3112-26
references: 14681207
references: Gastroenterology. 2009 May;136(5):1741-9.e6
references: 19208345